Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario by Choi, Yun-Hee et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
Hereditary Cancer in Clinical 
Practice
Open Access Research
Penetrance of colorectal cancer among MLH1/MSH2 carriers 
participating in the colorectal cancer familial registry in Ontario
Yun-Hee Choi1,2, Michelle Cotterchio3,4, Gail McKeown-Eyssen5,6, 
Monga Neerav3, Bharati Bapat7,8, Kevin Boyd3, Steven Gallinger7,9,10, 
John McLaughlin1,3,5, Melyssa Aronson11 and Laurent Briollais*1,5
Address: 1Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, Toronto, Canada, 2Department of Epidemiology and 
Biostatistics, University of Western Ontario, London, Canada, 3Division of Preventive Oncology, Cancer Care Ontario, Toronto, Canada, 4Division 
of Population Studies and Surveillance, Cancer Care Ontario, Toronto, Canada, 5Dalla Lana School of Public Health, University of Toronto, 
Toronto, Canada, 6Department of Nutritional Sciences, University of Toronto, Toronto, Canada, 7Fred A. Litwin Centre for Cancer Genetic, Samuel 
Lunenfeld Research Institute, Toronto, Canada, 8Laboratory of Medicine and Pathobiology, Mount Sinai Hospital, Toronto, Canada, 9Department 
of Surgery, University of Toronto, Toronto, Canada, 10Ontario Familial Colon Cancer Registry, Ontario Cancer Genetics Network, Toronto, Canada 
and 11Dr. Zane Cohen Digestive Disease Clinical Research Centre, Mount Sinai Hospital, Toronto, Canada
Email: Yun-Hee Choi - Yun-Hee.Choi@schulich.uwo.ca; Michelle Cotterchio - Michelle.Cotterchio@cancercare.on.ca; Gail McKeown-
Eyssen - gail.eyssen@utoronto.ca; Monga Neerav - Neerav.Monga@cancercare.on.ca; Bharati Bapat - Bapat@lunenfeld.ca; 
Kevin Boyd - Kevin.Boyd@cancercare.on.ca; Steven Gallinger - sgallinger@rogers.com; John McLaughlin - John.Mclaughlin@cancercare.on.ca; 
Melyssa Aronson - maronson@mtsinai.on.ca; Laurent Briollais* - laurent@lunenfeld.ca
* Corresponding author    
Abstract
Background: Several DNA mismatch repair (MMR) genes, responsible for the majority of Lynch
Syndrome cancers, have been identified, predominantly MLH1 and MSH2, but the risk associated
with these mutations is still not well established. The aim of this study is to provide population-
based estimates of the risks of colorectal cancer (CRC) by gender and mutation type from the
Ontario population.
Methods: We analyzed 32 families segregating MMR mutations selected from the Ontario Familial
Colorectal Cancer Registry and including 199 first-degree and 421 second-degree relatives. The
cumulative risks were estimated using a modified segregation-based approach, which allows
correction for the ascertainment of the Lynch Syndrome families and permits account to be taken
for missing genotype information.
Results: The risks of developing CRC by age 70 were 60% and 47% among men and women
carriers of any MMR mutation, respectively. Among MLH1 mutation carriers, males had significantly
higher risks than females at all ages (67% vs. 35% by age 70, p-value = 0.02), while the risks were
similar in MSH2 carriers (about 54%). The relative risk associated with MLH1 was almost constant
with age (hazard ratio (HR) varied between 5.5-5.1 over age 30–70), while the HR for MSH2
decreased with age (from 13.1 at age 30 to 5.4 at age 70).
Conclusion: This study provides a unique population-based study of CRC risks among MSH2/
MLH1 mutation carriers in a Canadian population and can help to better define and understand the
patterns of risks among members of Lynch Syndrome families.
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Introduction
Lynch Syndrome, also referred to as Hereditary non-poly-
posis colorectal cancer (HNPCC) is an autosomal domi-
nant condition which predisposes carriers to both
colorectal and extra-colonic cancers [1]. Several DNA mis-
match repair (MMR) genes responsible for the majority of
Lynch Syndrome cancers have been identified, predomi-
nantly MLH1 and MSH2 [2]. An understanding of risk
associated with MMR mutations is important to assist in
decisions about prophylactic surgery, annual screening
and chemoprevention and to help allay psychological dis-
tress related to the uncertainty of colorectal cancer (CRC)
predisposition among Lynch Syndrome family members
[1].
Despite this importance, only a small number of studies
provided penetrance estimates for these gene mutations.
In addition, most of them studied populations from Fin-
land, Scotland, the Netherlands and Nebraska [3-6] and it
is unlikely that they are generalizable to the Canadian
population as genetic mutations, lifestyle and environ-
mental factors may differ. Moreover, most previous stud-
ies focused on families with a very strong history of
cancers associated with the Lynch Syndrome and the
derived penetrance estimates are only valid for families
with comparable family history. Our study provides pop-
ulation-based estimates of penetrance by age, sex and
mutated gene for CRC cases identified through the
Ontario Familial Colorectal Cancer Registry (OFCCR) [7]
and selected to be representative of families likely to har-
bour MMR mutations. We also used an ascertainment-cor-
rected segregation approach to correct for the specific
ascertainment and missing mutation information. There-
fore, our analyses reduce the chance for biases and pro-
vide penetrance estimates that are applicable to a larger
population of CRC cases harbouring MMR mutations.
Materials and methods
Study population
The OFCCR is one of six international registries estab-
lished by the National Cancer Institute (NCI) as a resource
for the study of CRC [7]. The OFCCR used the population-
based Ontario Cancer Registry (OCR) to identify incident
CRC cases (probands), aged 20–74, diagnosed July 1997
to July 2000. With physician consent, colorectal cases
were contacted by a letter describing the study and
requesting completion of a family history questionnaire
(FHQ) which ascertained birth, death and disease history
for first- and second-degree relatives. This information
was used by genetic counselors to produce family pedi-
grees and to classify families as either 1) Amsterdam 1, 2)
Familial Risk which included early-onset CRC and/or
extra-colonic cancer in proband or relative, or family his-
tory of multiple CRC and/or extra-colonic cancers, 3) Spo-
radic/low risk with no family history of CRC [7].
Probands from Amsterdam 1 and Familial Risk families
were interviewed by counselors to clarify information
regarding all first-degree relatives, complete the pedigree
to include all second-degree relatives, and ascertain full
cancer histories. A randomized sample of 25% of the spo-
radic/low risk cases was also studied but because the prev-
alence of MMR germline mutations is very low in the
general population, around 1:3139 [8], this group was not
further considered in the penetrance study. Indeed, only
one individual in this group was found mutation carrier
after tumor analysis and germline testing.
Whenever possible, probands' tumours were first screened
for microsatellite instability (MSI) and immunohisto-
chemistry (IHC). Germline mutation analysis of MSH2,
MLH1  and/or  MSH6  genes was initiated in probands
based on MSI-high and/or IHC deficient tumours results.
Germline screening of a specific MMR gene was guided by
IHC deficiency for a specific MMR protein. Germline
mutations were also assessed among probands with MSI-
low or microsatellite stable (MSS) tumours if their
tumours exhibited MMR protein deficiency when assessed
by IHC [9]. Probands were also screened for germline
mutations in MLH1 and MSH2 when the tumours were
MSI-high and IHC intact, or where tumours were not
available for probands in Amsterdam 1 families. Testing
for MMR genes involved sequence analysis (MSH2,
MLH1, MSH6) and Multiplex Ligation-dependent Probe
Amplification (MLPA) (MSH2, MLH1) of genomic DNA
obtained from blood samples [9].
For each proband found to carry an MMR mutation, all
first- and second-degree relatives on the "at-risk side" of
the proband's pedigree were considered to be eligible for
the present study. Blood samples from these relatives were
obtained in two stages. First, the OFCCR had requested
blood samples from all probands' first-degree relatives,
together with all second-degree relatives who had had
cancer or who were a first-degree relative of a family mem-
ber with cancer, and who resided in North America, most
European countries, or the Caribbean. Second, to ensure
as many kin as possible were ascertained for the present
study, we requested blood from all probands' second-
degree relatives who had not previously been contacted by
the OFCCR. Inclusion of these additional second-degree
relatives was important to avoid over representation of
relatives with a cancer diagnosis and resultant upwardly
biased risk estimates.
Mutations in the MMR genes were ascertained from
genomic DNA for all participants from whom blood sam-
ples could be obtained. For deceased relatives, obligate
gene mutation carriers were defined as persons with a
descendent with a MMR gene mutation. Therefore, the
final retrospective study cohort included all living MSH2,Hereditary Cancer in Clinical Practice 2009, 7:14 http://www.hccpjournal.com/content/7/1/14
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MLH1 and MSH6 mutation carriers, and all deceased obli-
gate gene mutation carriers. There were 446 probands eli-
gible for our study (i.e., with blood sample available, with
consent to contact their relatives, satisfying the Amster-
dam 1 or other familial risk criteria, see above). Of these,
358 were tested for IHC (80%), 346 for MSI (77%), and
379 for either IHC or MSI (85%). Our final cohort
included 32 probands found to carry a MMR mutation
and their relatives. There were 27 probands from Amster-
dam 1 families and 5 from other familial risk families. The
relatives consisted of 199 first-degree and 421 second-
degree relatives, from whom 56 and 41, respectively, were
CRC cases (see Table 1). The number of blood samples
available was 71 and 56, respectively, in first- and second-
degree relatives from whom 38 and 22 were tested muta-
tion positive (see Table 1). Survival analyses with the clas-
sical Kaplan-Meier estimator [10] were carried out on the
sample of individuals with blood available. The modified
segregation-based approach (see methods section) was
able to use the full cohort of individuals (i.e. with or with-
out blood available) but age at diagnosis or at examina-
tion was required for the analysis. This was available for
506 individuals of the 622 recruited.
The Ethic approval was obtained from Mount Sinai Hos-
pital Research Ethics Board for this research project.
Verification of cancer diagnoses in relatives carrying a 
MMR gene mutation
The pathology and date of diagnosis of all subject-
reported CRC in a first- or second-degree relative were ver-
ified where possible using pathology reports obtained
from the OCR, other cancer registries outside of Ontario,
hospital discharge data, death certificates, and reports
from Regional Cancer Centres and Princess Margaret Hos-
pital, the main cancer hospital in Toronto. If only a death
certificate was available, it was reviewed. We attempted to
verify cancer diagnoses reported among relatives living in
other countries by requesting a pathology report from the
relevant cancer registry or hospital. All probands had their
colorectal cancer diagnosis confirmed by pathology
reports (100%), as required for study eligibility. Of the
622 first- and second-degree relatives identified in the 32
mutation positive families, 61% of CRCs identified were
confirmed by medical records and 38% of relatives iden-
tified as deceased were confirmed by death records found
in the mortality database.
Identification of probands/families carrying a MMR gene 
mutation
Microsatellite instability (MSI) analysis
Written informed consent was obtained from 99.6% of
OFCCR participants for the collection of tumour tissue for
use in cancer research. Colorectal tumour blocks were col-
lected from all eligible patients. Tumour DNA was
extracted from paraffin embedded matched normal and
tumour tissue specimens and tested for MSI status, using
a panel of 5–10 microsatellite markers recommended by
the National Institute of Health [11]. MSI was defined as
the presence of altered/additional bands in the polymer-
ase chain reaction (PCR) amplified product of tumour
DNA in comparison with the matched normal DNA sam-
ples obtained from the adjacent normal colon. Tumours
were designated MSI-high if ≥ 40% of the markers show
altered band patterns, MSI-low if there is < 40% instabil-
ity, and MSS if there was no instability [11].
MMR gene mutation analysis
MMR (MSH2, MLH1, MSH6) mutational analysis was
performed on DNA from peripheral blood lymphocytes
or lymphoblastoid cell lines. Large genomic deletions/
duplications in MSH2 and MLH1 genes were identified by
MLPA [12] and, if absent, underlying germline mutations
were further screened by genomic DNA sequencing [9].
Briefly, the entire coding regions of the MSH2 (16 exons)
and MLH1 (19 exons) genes were amplified by PCR and
screened for mutations using ABI 377 automated
sequencer. Similar functional analysis was also performed
for MSH6 gene using exon-by-exon sequencing strategy.
Functional mutations were confirmed by assessing pub-
lished literature, as well as from the human genome muta-
tion database [13] and the International Collaborative
Group-HNPCC database (InSIGHT). We used the compu-
tational programs Polymorphism Phenotyping to predict
the pathogenicity of novel MMR alterations http://genet
ics.bwh.harvard.edu/pph/[14] and Sorting Intolerant
From Tolerant http://blocks.fhcrc.org/sift/SIFT.html[15].
The description of the mutations found in this study is
given in Table 1.
Statistical Methods
Kaplan-Meier survival analysis
For the cohort of proband's family members, Kaplan-
Meier survival analysis [10] was used to estimate the age-
specific cumulative CRC incidence, with the correspond-
ing 95% confidence interval (CI), where observation time
was taken from birth to the earlier of age at diagnosis of
CRC or current age. The analysis was stratified by: (a)
MMR mutation status (MSH2  or  MLH1); (b) gender
among MMR mutation carriers and non-carriers.
Segregation-based analysis
To account for missing genotype data and the non-ran-
dom ascertainment of the families, we fitted likelihood-
based segregation analyses [16,17]. This allowed the esti-
mation of the cumulative risk (penetrance) associated
with either any Lynch Syndrome mutation or specific
MLH1 or MSH2 mutations, in males and females. Based
on preliminary data analysis, we found that a log-logistic
regression model for the hazard function (see Equation
(1) in Appendix 1) fitted the data well, and we used this
to estimate the cumulative risk of developing CRC by eachHereditary Cancer in Clinical Practice 2009, 7:14 http://www.hccpjournal.com/content/7/1/14
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decade of age, for each type of mutation. The log-logistic
model had the added advantage that it allowed the hazard
rate to follow a non-monotonic function, in which the
risk initially increased with age and then decreased, as
observed in Jenkins et al. [18].
The analyses were adjusted for ascertainment by condi-
tioning the likelihood of the family's observed genotypes
on the observed phenotypes in the family members, given
their ages at examination (see Appendix 2). Thus, we
obtain the maximum likelihood estimates of the needed
Table 1: Description of MMR mutation-carrying participants – mutation information and counts of kin (family size), kin with blood, 
colorectal cancer (CRC) amongst kin, and mutation carriers amongst kin by relative degree
No. of kin 
reported
No. of kin with CRC 
reported
No. of kin with 
blood
No. of mutation 
carriers
Gene Germline 
Mutation
Mutation 
Consequence
1st 2nd 1st 2nd 1st 2nd 1st 2nd
MLH1 c.1852_1853 
AA>GC
p.Lys618Ala 4 16 2 0 2 5 0 0
c.1689_1690insA p.Ile563IlefsX4 3 12 1 2 2 0 0 0
c.1732_1896del Exon 16 del 6 11 2 0 2 4 1 3
c.116+5 G>C Splice-site defect 7 13 1 1 2 0 1 0
c.793C>T p.Arg265Cys 10 23 2 5 1 6 1 1
c.793C>T p.Arg265Cys 7 25 1 5 2 5 1 0
c.346delA p.Thr116GlnfsX20 2 5 1 2 0 0 0 0
c.731G>A p.Gly244Asp 6 5 2 0 5 0 5 0
c.790+2T>C Splice-site defect 9 19 3 1 6 7 3 3
c.298C>T p.Arg100X 7 6 2 0 1 0 0 0
c.1975C>T p.Arg659X 3 5 2 3 3 0 0 0
c.2223_2231del In-frame deletion 9 11 2 1 3 0 2 0
c.793C>T p.Arg265Cys 4 11 1 1 2 0 1 0
c.350C>T Thr117Met 9 10 1 0 4 0 3 0
Total: 86 172 23 21 35 27 18 7
MSH2 c.1216C>T p.Arg406X 5 5 2 0 1 1 0 0
c.1165C>T p.Arg389X 3 7 1 2 1 1 1 1
c.1277_1386del Exon 8 deletion 5 18 4 3 1 2 1 0
c.2075G>T p.Gly692Val 5 10 1 3 0 0 0 0
c.136_164del p.His46GlyfsX35 3 5 1 2 2 0 2 0
c.2135_2136insT p.Val712ValfsX4 5 11 2 1 1 0 0 0
c.942+3A>T Splice-site defect 13 33 3 1 1 3 1 0
c.1511-2A>G Splice-site defect 9 3 1 0 2 1 2 1
c.363T>G p.Tyr121X 10 23 3 1 7 1 1 0
c.1_1386del Exons 1–8 deletion 9 21 3 0 4 6 3 3
c.1705_1706del p.Glu569IlefsX2 3 7 1 2 1 4 1 3
c.965G>T p.Gly322Asp 6 14 1 0 1 0 0 0
c.942+3A>T Splice-site defect 5 9 2 1 2 1 2 1
c.645+1G>A Splice-site defect 5 7 1 2 1 0 1 0
c.1705_1706del p.Glu569IlefsX2 5 12 2 0 2 0 0 0
c.1165C>T p.Arg389X 7 22 3 1 3 6 2 3
c.1165C>T p.Arg389X 3 5 1 1 1 2 1 2
Total: 101 212 32 20 31 28 18 14
MSH6 c.3335_3336insA
TGA
p.Asp1112GlufsX2 12 37 1 0 5 1 2 1
Total: 12 37 1 0 5 1 2 1
Grand total: 199 421 56 41 71 56 38 22
(1st = first degree relatives, 2nd = second degree relatives)Hereditary Cancer in Clinical Practice 2009, 7:14 http://www.hccpjournal.com/content/7/1/14
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parameters by maximizing this ascertainment-corrected
retrospective likelihood [16,17] into the software Mendel
[19] and used the parameters to estimate the cumulative
risk of CRC at a given age, using the penetrance function
in Equation (2) of the Appendix 1. For this analysis, the
ascertainment correction was based on the first degree rel-
atives of probands (i.e., the proband, his/her sibs and
their parents), where probands carried a MMR mutation.
For all analyses, the 95% CI for the cumulative risk by a
given age was estimated using simulation of 1,000 sets of
parameters, assuming a multivariate normal distribution
of the parameters being estimated [18].
Results
Distribution of missing ages and ages at onset in the 
families
We had information on age at CRC onset for all 32
probands. This information was missing for 6 out of 97
affected relatives but 3 of them had their age at examina-
tion available. Among the 493 unaffected individuals
(255 males and 238 females), age at examination was
missing for 113 (60 males and 53 females). Among
affected individuals (probands and relatives), the mean
age at onset was 45.1 (n = 25, standard deviation (s.d.) =
13.3) in MSH2 carriers, 53.6 (n = 21, s.d. = 12.3) among
MLH1 carriers and 51.4 (n = 76, s.d. = 14.6) for individu-
als with unknown mutation status. Only one individual
was negative for MSH2 among the affected relatives.
Kaplan-Meier analysis
Descriptive analyses with the Kaplan-Meier (KM) estima-
tor were carried out on the sample of kin with blood and
age information available. The kin included 60 individu-
als who were positive for any MMR mutation (16 affected
and 44 unaffected individuals) and 62 who were negative
(1 affected and 61 unaffected individuals). In addition,
we also estimated separately the cumulative risk in 352
individuals with unknown mutation status (77 affected
Table 2: Estimates of cumulative risks (%) to ages 30, 50, and 70 (and corresponding 95% confidence intervals) for colorectal cancer 
stratified by MMR mutation status and gender using Kaplan-Meier analysis
Mutation Gender Age 30 Age 50 Age 70
Carrier of any MMR mutation Carrier Male
(n = 27)
- 21 (0, 39) 67 (3, 89)
Female
(n = 33)
4 (0, 10) 35 (6, 55) 51 (16, 71)
Combined
(n = 60)
2 (0, 6) 29 (10, 44) 55 (28, 72)
MLH1 carrier Male
(n = 13)
- 40 (0, 70) 70 (0, 94)
Female
(n = 12)
- - 38 (0, 68)
Combined
(n = 25)
- 16 (0, 34) 50 (4, 73)
MSH2 carrier Male
(n = 12)
-- -
Female
(n = 23)
5 (0, 15) 61 (9, 83) 61 (9, 83)
Combined
(n = 35)
3 (0, 10) 36 (6, 56) 56 (15, 77)
Non-carrier of all mutations Male
(n = 22)
-- -
Female
(n = 40)
- 7 (0, 19) 7 (0, 19)
Combined
(n = 62)
- 4 (0, 11) 4 (0, 11)
Any mutation unknown Male
(n = 195)
2 (0, 5) 23 (14, 31) 46 (34, 57)
Female
(n = 157)
4 (0, 7) 13 (6, 20) 41 (27, 52)
Combined
(n = 352)
3 (1, 5) 19 (13, 24) 44 (35, 52)
(n represents the number of kin with blood available and age information available)Hereditary Cancer in Clinical Practice 2009, 7:14 http://www.hccpjournal.com/content/7/1/14
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Table 3: Estimates of cumulative risks (%) at ages 30, 50 and 70 (and corresponding 95% confidence intervals) for colorectal cancer 
among mutation carriers and non-carriers (any MMR, MLH1, MSH2) based on the segregation analysis.
Mutation Gender Age 30 Age 50 Age 70
Carrier of any MMR mutation Male 1 (0, 2) 23 (10, 33) 60 (35, 73)
Female 1 (0, 1) 15 (7, 23) 47(27, 60)
Combined 1 (0, 1) 18 (11, 25) 53 (37, 64)
MLH1 Carrier Male 1 (0, 2) 25 (7, 51) 67 (27, 89)
Female 0 (0, 1) 8 (2, 19) 35 (10, 59)
Combined 0 (0, 12) 13 (4, 30) 44 (19, 70)
MSH2 Carrier Male 1 (0, 2) 21 (1, 36) 55 (2, 75)
Female 1 (0, 2) 20 (1, 32) 53 (2, 70)
Combined 1 (0, 2) 20 (1, 29) 54 (3, 69)
Non-carrier of all mutations Male 0 (0, 1) 2 (0, 7) 10 (1, 27)
Female 0 (0, 1) 1 (0, 6) 6 (1, 24)
Combined 0 (0, 1) 2 (0, 6) 9 (2, 24)
Age-specific cumulative risks of colorectal cancer (CRC) among carriers and non-carriers of MMR (any MMR, MLH1, MSH2)  mutation specified by gender, based on the segregation analysis Figure 1
Age-specific cumulative risks of colorectal cancer (CRC) among carriers and non-carriers of MMR (any MMR, 
MLH1, MSH2) mutation specified by gender, based on the segregation analysis.Hereditary Cancer in Clinical Practice 2009, 7:14 http://www.hccpjournal.com/content/7/1/14
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and 275 unaffected individuals). By age 70, about two
thirds of male carriers and one half of female carriers of
any MMR mutation had experienced CRC (Table 2).
Importantly, the risk among those with unknown muta-
tion status was considerably closer to that of carriers than
non-carriers between the two estimates (Table 2). Thus,
omitting the unknown group or combining their esti-
mates with another genotype category could lead to seri-
ous biases.
Modified segregation-based analysis
The modified segregation-based approach was able to use
the full cohort of probands and their kin, with or without
blood available. After removing individuals without
information on age at diagnosis or examination, the final
sample included 506 individuals out of the 622 recruited.
Therefore, the estimation of the cumulative risk with the
segregation approach took into account 32 probands, 60
kin who tested positive for any MMR mutation, 62 kin
who tested negative, and 352 kin with unknown mutation
status. These 32 probands and 352 kin could not be
included in the KM estimation of carriers and non-carri-
ers.
As assessed by segregation analysis, 60% of male and 47%
of female carriers of any MMR gene mutation had devel-
oped CRC by age 70. These risks were 81% and 72% by
age 90, respectively. The cumulative risk appeared higher
for men than for women at all ages (Table 3 and Figure 1),
although a formal test of difference was not significant
(Wald Chi-square test; p-value = 0.25). This arose because
male carriers of MLH1 gene mutations had a significantly
higher risk of cancer than female carriers at all ages (67%
vs. 35% by age 70, p-value = 0.02) (Table 3 and Figure 1),
while male and female carriers of MSH2 mutations had
similar cumulative risks of disease (≈ 54%, p-value = 0.89)
(Table 3). Among men, the estimated risk was higher
among carriers of MLH1 mutations than MSH2 mutations
(e.g. 67% vs. 55% by age 70), while the opposite was
observed among women (e.g. 35% vs. 53% by age 70).
For  MLH1  mutations, the age-specific risk of cancer
among male carriers (the hazard rate) increased to about
age 70 but remained relatively constant thereafter (Figure
2), while female carriers continued to experience an
increase in risk after age 70. However, for MSH2 mutation
carriers of both sexes, risk increased only until about age
70 and stabilized afterwards. As observed in previous
studies, male carriers were at higher risk than female car-
riers for MLH1 but not for MSH2 mutations.
Estimates of hazard ratios (HRs) for CRC at different ages
are presented in Table 4. Estimates for males and females
were combined in the table due to their large confidence
intervals. The effect of MLH1 on CRC was almost constant
with age (the HR varied between 5.5 at age 30 and 5.1 at
age 70). MSH2 had a stronger effect on CRC and exhibited
a decreasing pattern with age (the HR fell from 13.1 at age
30 to 5.4 at age 70). The global effect of any MMR muta-
Gender-specific and/or mutation-specific hazard rate estimates of developing colorectal cancer (CRC) in MLH1 gene (left) and  MSH2 gene (right) mutations, based on the segregation analysis Figure 2
Gender-specific and/or mutation-specific hazard rate estimates of developing colorectal cancer (CRC) in 
MLH1 gene (left) and MSH2 gene (right) mutations, based on the segregation analysis.
Table 4: Estimated hazard ratios of colorectal cancer risk at ages 
30, 50 and 70 (and corresponding 95% confidence interval) in 
gene mutation carriers (any MMR, MLH1, MSH2) compared with 
that in the general population, based on the segregation 
analysis.
Mutation Age 30 Age 50 Age 70
Any MMR 10.5 (2.5, 46.9) 8.8 (2.3, 40.1) 5.5 (1.8, 25.0)
MLH1 5.5 (0.8, 53.6) 6.5 (1.4, 41.8) 5.1 (1.3, 26.9)
MSH2 13.1 (0.3, 78.8) 9.3 (0.3, 44.4) 5.4 (0.3, 24.5)Hereditary Cancer in Clinical Practice 2009, 7:14 http://www.hccpjournal.com/content/7/1/14
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tion on CRC was significant and showed a decreasing
trend with age (the HR fell from 10.5 at age 30 to 5.5 at
age 70).
Discussion
To our knowledge, only three other studies [6,18,20] have
provided population-based estimate of CRC risk in Lynch
Syndrome families but none of them was reported in
North America. While our results confirmed a relatively
high penetrance associated with MMR gene mutations,
our risk estimates seem lower than many clinic-based esti-
mates [3,5,21-26].
Previous studies have estimated the risk of developing
CRC among MMR gene mutation carriers in Lynch Syn-
drome families to vary between 30 to 100% [3-6,21-26],
where the lowest rates are generally reported in women
from population-based studies. The excess of risk in males
compared to females found in several studies [3,4,6] was
also confirmed in our analyses. This could suggest that
females are protected from CRC; perhaps due to environ-
mental/reproductive factors unique to women or to a sex-
linked modifier gene. We also found a gender specific
mutation effect with a higher risk in male carriers of
MLH1 mutations (67%) vs. carriers of MSH2 mutations
(55%), while the opposite was observed among women
carriers (35% for MLH1 vs. 53% for MSH2), by age 70.
Our study also showed that age-specific risk (hazard ratio)
associated with MLH1  was almost constant with age,
while the risk associated with MSH2 decreased with age.
The same trends were also suggested in a recent study [18].
If differences in risks observed for MLH1 and MSH2 are
confirmed, then the distribution of the types of MMR
mutations could have a profound impact on the cancer
risk.
Our cumulative risk estimates are close to the lower esti-
mates previously published. They are slightly higher than
another recent population-based study [18], but this latter
selected exclusively early-onset probands. Several factors
might explain the discrepancies with the previous pene-
trance estimates. First, methods of kindred ascertainment
varied between studies, and the distribution of factors
which likely affect risk may also vary across studies con-
ducted in different countries. Because MMR mutations are
rare in the general population [6,8], most penetrance esti-
mates are derived from high-risk Lynch Syndrome fami-
lies, who usually satisfy the original or revised Amsterdam
criteria [27]. Because these designs are enriched with
mutation carriers, they could be more efficient for esti-
mating penetrance than population-based designs [17]
but also more prone to biases [28,29]. Extrapolation to
the general population (i.e. all CRC cases) is not possible
unless appropriate ascertainment correction is applied to
account for the nonrandom sampling. This was per-
formed in this study by the use of the modified segrega-
tion-based analysis. Our recent simulation studies [17]
confirmed the validity of our ascertainment-corrected
approach. Second, it is likely that there exist other genetic
and non-genetic contributors to HNPCC, other than a
MMR mutation, that could also aggregate within families.
Some of our additional analyses suggest the role of a sec-
ond major gene within these families, but further work is
still needed to distinguish its effect from a common envi-
ronmental factor. Third, data quality was improved in the
present investigation compared to previous studies in two
ways. Previous studies, unlike the present study, were con-
ducted before techniques were available to test for MMR
gene mutations so could not determine accurately the sta-
tus of the MMR gene [22,23]. In addition, missing geno-
type is a common problem in family studies and the
classical analysis approaches for time-to-onset data such
as Kaplan-Meier estimation or Cox regression model, in
their original formulations, cannot solve this problem. In
this study, the use of a modified segregation-based
approach allows inferences on the missing genotypes by
using the Mendelian transmission probabilities and gene-
alogical relationships. As a consequence, the segregation-
based analysis was able to use the information on 32
probands and 352 kin who were not included in the KM
analyses, resulting in more precise and potentially less
biased penetrance estimates.
Our estimated cumulative risks among non-carriers are
much higher than observed in the general population, for
example we estimated a combined (MLH1/MSH2) cumu-
lative risk of 9% by age 70 while it is about 2% in the US
population. The possible discrepancy between our cumu-
lative risk estimates in non-carriers vs. those published in
the US general population could be due to the fact that
our sample is enriched with affected individuals who
could have a very different genetic and non-genetic risk
profile than the general population. Therefore, even if our
design and ascertainment correction approach tend to
yield estimates that are closer to the general population,
the difference seen between the two estimates can reflect a
difference in the distribution of risk factors in our sample
compared to the general population [28].
In summary, many sources of bias have been reduced in
this study, in part through the choice of study subjects and
use of the modified segregation-based analyses. However,
several limitations may still exist. First, the sample size is
relatively small for a risk estimation study and the confi-
dence intervals are large, especially for estimating muta-
tion-specific and gender-specific penetrances. This
problem was only partly overcome by using the modified
segregation-based approach. Efficiency was also improvedHereditary Cancer in Clinical Practice 2009, 7:14 http://www.hccpjournal.com/content/7/1/14
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by selecting preferentially probands carrying a mutation
and thus they are more informative than random
probands [17]. Second, inaccuracy of cancer history might
introduce error. While we attempted to confirm with
pathology reports all reported family members with a
CRC diagnosis, this was not possible for all cases. How-
ever, recent research conducted in Ontario found that
proband's reports of relatives' cancer diagnoses are fairly
accurate; 93% of proband-reported CRC among first-
degree relatives were verified by either hospital records,
cancer registry or death certificates, though reporting was
less accurate for second-degree relatives with only 72% of
reported CRCs verified [30]. Third, some studies classified
tumours as MSI-high if > 30% of the markers show altered
band patterns. Because we identified MSI-high tumours as
those with altered band patterns in > 40% of markers, we
may have missed some carriers. However, because this
classification was not associated with the proband's fam-
ily history, it is unlikely that this biased our penetrance
estimates. Finally, we assumed that the probands selected
are representative of the entire population of CRC families
in Ontario. Because of our relatively small sample size,
this hypothesis is difficult to assess and deviation from
this hypothesis could lead to a selection bias. Although
unlikely, it is possible that the estimates of penetrance
could be biased upwards if families carrying the gene par-
ticipated differentially according to the prevalence of can-
cer in the family.
In conclusion, this study provides a unique population-
based study of CRC risks among MSH2/MLH1 mutation
carriers in a Canadian population and can help to better
define and understand the patterns of risks among mem-
bers of Lynch Syndrome families.
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Appendix 1: Log-logistic regression model
We consider a log-logistic regression model for investigat-
ing the dependence of age at onset of colorectal cancer on
mutation carrier status and gender.
Suppose T is the age of onset associated with genotype G
and other covariates x. We assume T follows the log-logis-
tic distribution, which has hazard function h(t|G) of the
form by
where x1 indicates the mutation carrier status for the MMR
gene (either MLH1, MSH2, or any) and xs distinguishes
between males (xs = 1) and females (xs = 2). Here, the
parameter λ > 0 is a scale parameter and ρ > 0 is a shape
parameter, which allows a non-monotonic hazard func-
tion: when ρ > 1, the hazard function is unimodal and
when ρ ≤ 1, it decreases monotonically.
Then, the corresponding penetrance function is defined
by the cumulative risk of a disease up to age t given the
genotype G and other covariates x, as
Appendix 2: Ascertainment-corrected 
retrospective likelihood
Our risk estimates (relative or cumulative) are based on an
ascertainment-corrected retrospective likelihood
approach. Correction was based on the conditional prob-
ability of the observed genotypes (G) given the observed
phenotypes (D) in the family and corrected for the ascer-
tainment event (A).
The ascertainment-corrected retrospective likelihood, L,
arising from a sample of n independent families for each
family size nf has the form
where Lf is the conditional likelihood of family f obtained
by dividing the likelihood contribution of family f, Nf, by
the probability of its being ascertained, Af.
For family f with nf family members, we define D = (D1, ...,
Dnf) and G = (G1, ..., Gnf) as the vector forms that represent
their phenotypes and genotypes, respectively, where the
phenotype is defined by the age at onset and affection sta-
tus, i.e. Di = (Ti, δi). The likelihood contribution for family
f can be expressed as a function of the genotypes of family
members given their phenotypes and ascertainment
event, i.e.,
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Here, P (D|G) in the numerator can be obtained using sur-
vival analysis approach,
where h(.) and S(.) represent hazard and survivor func-
tions, respectively, defined in Appendix 1, P(G) is the gen-
otype probability of family members based on Hardy-
Weinberg equilibrium and Mendelian transmission prob-
abilities, and the denominator, P(D, A), represents the
probability of observing the phenotypes of individuals
who qualify for ascertainment. For more details, refer
Choi et al. [17].
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